X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The funding will be used for Phase 2b clinical study evaluating Vaxart’s oral pill XBB COVID-19 vaccine candidate, VXA-CoV2-1.1-S, against an approved mRNA vaccine comparator.
Lead Product(s): VXA-CoV2-1.1-S
Therapeutic Area: Infections and Infectious Diseases Product Name: VXA-CoV2-1.1-S
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: BARDA
Deal Size: $9.2 million Upfront Cash: Undisclosed
Deal Type: Funding January 19, 2024
Details:
VXA-GI.1.NN & VXA-GII.4.NN, an orally administered bivalent norovirus vaccine candidate. It is being evaluated in phase 1 clinical trials for the treatment of Norovirus infection in lactating mothers.
Lead Product(s): VXA-GI.1.NN,VXA-GII.4.NN
Therapeutic Area: Infections and Infectious Diseases Product Name: VXA-GI.1.NN
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2023
Details:
VXA-G1.1-NN is a oral norovirus vaccine elicits mucosal homing B cells that are Enriched for IgA production and vaccine antigens delivered to the mucosal surface.
Lead Product(s): Ad5 Norovirus GI.1 Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: VXA-G1.1-NN
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2023
Details:
VXA-G1.1-NN oral norovirus vaccine elicits mucosal homing B cells that are Enriched for IgA production and vaccine antigens delivered to the mucosal surface.
Lead Product(s): VXA-G1.1-NN
Therapeutic Area: Infections and Infectious Diseases Product Name: VXA-G1.1-NN
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2023
Details:
VXA-G1.1-NN and VXA-GII.4-NS oral norovirus vaccine elicits mucosal homing B cells that are Enriched for IgA production and vaccine antigens delivered to the mucosal surface.
Lead Product(s): VXA-G1.1-NN,VXA-GII.4-NS
Therapeutic Area: Infections and Infectious Diseases Product Name: VXA-G1.1-NN
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 06, 2023
Details:
VXA-G1.1-NN and VXA-GII.4-NS Oral Norovirus Vaccine Elicits Mucosal Homing B cells that are Enriched for IgA Production and Vaccine antigens delivered to the mucosal surface.
Lead Product(s): VXA-G1.1-NN,VXA-GII.4-NS
Therapeutic Area: Infections and Infectious Diseases Product Name: VXA-G1.1-NN
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2023
Details:
VXA-G.1.1-NN (norovirus vaccine) that produces mucosal antibodies locally in the intestine, in addition to systemic antibodies that circulate in the blood, may better protect against norovirus infection than an injectable vaccine.
Lead Product(s): VXA-GI.1.NN
Therapeutic Area: Infections and Infectious Diseases Product Name: VXA-GI.1.NN
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2023
Details:
Vaxart is developing a bivalent tablet norovirus vaccine. Because norovirus is a pathogen that infects the small intestine, Vaxart believes a vaccine that produces mucosal antibodies locally in the intestine, may better protect against norovirus infection.
Lead Product(s): Norovirus Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: VXA-G1.1-NN
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Bill & Melinda Gates Foundation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing December 01, 2022
Details:
VXA-CoV2-1, an oral tablet COVID-19 vaccine triggers mucosal immune responses in humans, is believed to be the first defense against airborne viruses, such as coronavirus and flu.
Lead Product(s): VXA-CoV2-1.1-S
Therapeutic Area: Infections and Infectious Diseases Product Name: VXA-CoV2-1.1-S
Highest Development Status: Phase IIProduct Type: Vaccine
Recipient: Syngene International Limited
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2022
Details:
VXA-CoV2-1.1-S (a Wuhan-based vaccine),stimulates IgG serum antibody responses against original strain of omicron variants, in phase II trial it demonstrated that trial met its primary safety and secondary immunogenicity endpoints.
Lead Product(s): VXA-CoV2-1.1-S
Therapeutic Area: Infections and Infectious Diseases Product Name: VXA-CoV2-1.1-S
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
